Search Results - "van Beers, Miranda M. C."

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice by van Beers, Miranda M. C., Sauerborn, Melody, Gilli, Francesca, Brinks, Vera, Schellekens, Huub, Jiskoot, Wim

    Published in Pharmaceutical research (01-10-2011)
    “…ABSTRACT Purpose To study the effect of oxidation on the structure of recombinant human interferon beta-1a (rhIFNβ-1a) and its immunogenicity in wild-type and…”
    Get full text
    Journal Article
  2. 2

    Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice by van Beers, Miranda M. C., Sauerborn, Melody, Gilli, Francesca, Brinks, Vera, Schellekens, Huub, Jiskoot, Wim

    Published in Pharmaceutical research (01-09-2010)
    “…ABSTRACT Purpose To study the influence of protein aggregation on the immunogenicity of recombinant human interferon beta (rhIFNβ) in wild-type mice and…”
    Get full text
    Journal Article
  3. 3

    Allergen Ara h 1 Occurs in Peanuts as a Large Oligomer Rather Than as a Trimer by van Boxtel, Evelien L, van Beers, Miranda M. C, Koppelman, Stef J, van den Broek, Lambertus A. M, Gruppen, Harry

    Published in Journal of agricultural and food chemistry (20-09-2006)
    “…Ara h 1, a major peanut allergen, is known as a stable trimeric protein. Nevertheless, upon purification of native Ara h 1 from peanuts using only size…”
    Get full text
    Journal Article
  4. 4

    Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene by Van Beers, Miranda M C, Gilli, Francesca, Schellekens, Huub, Randolph, Theodore W, Jiskoot, Wim

    Published in Journal of pharmaceutical sciences (01-01-2012)
    “…Aggregates play a major role in the immunogenicity of recombinant human interferon beta (rhIFNβ), a protein used to treat multiple sclerosis. A possible cause…”
    Get more information
    Journal Article
  5. 5

    On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis by van Beers, Miranda M C, Jiskoot, Wim, Schellekens, Huub

    Published in Journal of interferon & cytokine research (01-10-2010)
    “…Like many other therapeutic proteins, recombinant human interferon beta (rhIFN-β) elicits undesirable immune responses. rhIFN-β-treated multiple sclerosis…”
    Get more information
    Journal Article
  6. 6

    Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta by van Beers, Miranda M.C., Sauerborn, Melody, Gilli, Francesca, Hermeling, Suzanne, Brinks, Vera, Schellekens, Huub, Jiskoot, Wim

    Published in Journal of immunological methods (31-01-2010)
    “…To date, the therapeutic efficacy of recombinant human proteins is limited by their potential to break B cell tolerance in patients. The formation of…”
    Get full text
    Journal Article
  7. 7

    Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory by Sauerborn, Melody, van Beers, Miranda M. C., Jiskoot, Wim, Kijanka, Grzegorz M., Boon, Louis, Schellekens, Huub, Brinks, Vera

    Published in Journal of clinical immunology (2013)
    “…Purpose The immunological processes underlying immunogenicity of recombinant human therapeutics are poorly understood. Using an immune tolerant mouse model we…”
    Get full text
    Journal Article
  8. 8

    Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins by van Beers, Miranda M. C., Bardor, Muriel

    Published in Biotechnology journal (01-12-2012)
    “…Adverse immune responses severely hamper the success of biopharmaceutical therapies. Possible clinical consequences include anaphylaxis, reduced drug half‐life…”
    Get full text
    Journal Article
  9. 9

    Micro-Flow Imaging as a quantitative tool to assess size and agglomeration of PLGA microparticles by van Beers, Miranda M.C., Slooten, Cees, Meulenaar, Jelte, Sediq, Ahmad S., Verrijk, Ruud, Jiskoot, Wim

    “…[Display omitted] The purpose of this study was to explore the potential of flow imaging microscopy to measure particle size and agglomeration of…”
    Get full text
    Journal Article
  10. 10

    A Flow Imaging Microscopy-Based Method Using Mass-to-Volume Ratio to Derive the Porosity of PLGA Microparticles by Sediq, Ahmad S, Waasdorp, Stephan K D, Nejadnik, M Reza, van Beers, Miranda M C, Meulenaar, Jelte, Verrijk, Ruud, Jiskoot, Wim

    Published in Journal of pharmaceutical sciences (01-11-2017)
    “…The release of drugs from poly(lactic-co-glycolic acid) (PLGA) microparticles depends to a large extent on the porosity of the particles. Therefore, porosity…”
    Get more information
    Journal Article